IL-13Rα1 Signaling in Atopic Dermatitis
Sriya V. Reddy, Zachary Bordeaux, Ahmed Rajeh, Jackson Adams, Ferda Cevikbas, Shawn G. Kwatra, Madan M. Kwatra
The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.
ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.
Read about our latest product developments and partnerships, industry advances and events.
IL-13Rα1 Signaling in Atopic Dermatitis
Sriya V. Reddy, Zachary Bordeaux, Ahmed Rajeh, Jackson Adams, Ferda Cevikbas, Shawn G. Kwatra, Madan M. Kwatra
Blocking multi-neuronal sensitization effects of IL-4 and IL-13 through Interleukin-13 receptor alpha 1 (IL-13Rα1) with eblasakimab
Yannick Miron, Paul Miller, Carl Firth and Ferda Cevikbas
Eblasakimab Improves Itch and Sleep Loss in Adult Patients with Moderate-to-severe Atopic Dermatitis in a Randomized, Double-blinded, Placebo-controlled, Phase 1 Study
Karen A. Veverka, Steven Tien Guan Thng, Eric Simpson
Eblasakimab, a Monoclonal Antibody Targeting IL‑13Rα1 Reduces Serum Biomarkers Associated with Atopy and Correlated with Disease Severity in Patients With Moderate‑to‑Severe Atopic Dermatitis
Ferda Cevikbas, Eric Simpson, Alison Ward, Steven Tien Guan Thng, Karen A. Veverka
Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers
Ferda Cevikbas, Alison Ward, Carl Firth, Karen Veverka
Eblasakimab monotherapy improves moderate-to-severe atopic dermatitis symptoms across anatomical regions in a Phase 1 study
Karen A. Veverka, Josemund Menezes, Steven Tien Guan Thng
1st International Societies for Investigative Dermatology Meeting, May 2023
Downstream effects of IL-13Rα1 blockade on Type 2 inflammation and Th1 immune axis activation in atopic dermatitis
Sriya V. Reddy, Zachary Bordeaux, Ahmad Rajeh, Darshan Sivaloganathan, Hannah Cornman, Anusha Kambala, Jackson Adams, Ferda Cevikbas, Shawn G. Kwatra, Madan M. Kwatra
1st International Societies for Investigative Dermatology Meeting, May 2023
Neuromodulation Beyond Itch is Blocked by Targeting IL‐13Rα1 with Eblasakimab
Yannick Miron, Paul Miller, Carl Firth and Ferda Cevikba
1st International Societies for Investigative Dermatology Meeting, May 2023
A novel ex vivo model of human hair follicle immune privilege collapse reveals the potential of farudodstat, a DHODH inhibitor, as a therapeutic for alopecia areata treatment
Thomas Rouille, Silvia Barbosa, Ana Steinhoff, Ilaria Piccini, Janin Edelkamp, Ferda Cevikbas, Marta Bertolini
1st International Societies for Investigative Dermatology Meeting, May 2023
Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study
Karen A. Veverka, Josemund Menezes, Steven Tien Guan Thng, Melinda Gooderham, Eric Simpson
31st European Academy of Dermatology and Venereology Congress (EADV), September 2022
New insights into neuronal itch mechanisms by targeting IL-13Rα1 with eblasakimab
Yannick Miron, Paul Miller, Carl Firth, and Ferda Cevikbas
Society for Investigative Dermatology (SID) Annual Meeting, May 2022
Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study
Karen A. Veverka, Josemund Menezes, Steven Tien Guan Thng, Eric Simpson
31st European Academy of Dermatology and Venereology Congress (EADV), September 2022
Eblasakimab, a monoclonal antibody targeting IL-13Ra1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis
Ferda Cevikbas, Jacob P. Thyssen, Eric Simpson, Alison Ward, Steven Tien Guan Thng, Karen A. Veverka
31st European Academy of Dermatology and Venereology Congress (EADV), September 2022
Interim analysis results from a Proof-of-Concept study for ASLAN004 in adult moderate-to-severe atopic dermatitis: a double blind, randomized, placebo-controlled study
Karen A. Veverka , Kenneth Kobayashi, Josemund Menezes , Nicola McIntyre, Alison Ward, April Armstrong, Steven Tien Guan Thng, Jonathan I. Silverberg
Spatial localization and functional role of IL-13Rα1 signalling in atopic dermatitis
Zachary A. Bordeaux, Ahmed Rajeh, Jackson Adams, Ferda Cevikbas, Shawn G. Kwatra, Madan M. Kwatra, Ph.D
51st Annual European Society for Dermatological Research (ESDR) Meeting, September – October 2022
Insight into novel itch pathways and spontaneous neuronal activity by targeting interleukin 13 receptor alpha 1 (IL13Rα1) with eblasakimab
Yannick Miron, Paul Miller, Carl Firth and Ferda Cevikbas
51st Annual European Society for Dermatological Research (ESDR) Meeting, September – October 2022
Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in vitro models
S.W. Jones, S.L Penman, N.S French, B.K Park, A.E Chadwick.